TrialThe lancet. HIV2025

Efficacy and safety of a mosaic HIV-1 vaccine regimen in men who have sex with men and transgender individuals (HVTN 706/HPX3002/Mosaico): a global, randomised, double-blind, placebo-controlled, phase 3 trial.

Susan P Buchbinder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.